



**Genmab A/S**

Kalvebod Brygge 43  
DK-1560 Copenhagen V  
Denmark  
Tel. +45 7020 2728  
www.genmab.com  
CVR no. 2102 3884

March 8, 2018

Dear Shareholder,

Please find enclosed an invitation to attend Genmab A/S' Annual General Meeting to be held on

**Tuesday, April 10, 2018 at 2:00 PM CEST at**  
Copenhagen Marriott Hotel  
Kalvebod Brygge 5  
DK-1560 Copenhagen V  
Denmark

The Annual General Meeting gives you an opportunity to hear about the many achievements made by Genmab in 2017. These include substantial progress with DARZALEX<sup>®</sup> (daratumumab), tisotumab vedotin and our early stage product pipeline, and we exceeded our financial goals.

The success of DARZALEX continued in 2017 with three new approvals - in Europe, the U.S., and Japan. We reported another strong set of clinical data for daratumumab - the ALCYONE study treating newly diagnosed multiple myeloma patients, for which regulatory applications were submitted in the U.S. and Europe in November. And many new studies of daratumumab were started.

DARZALEX became a blockbuster drug, reaching over USD 1 billion in sales in 2017. Our collaboration partner, Janssen Biotech, has done a fabulous job commercializing this ground-breaking medicine, making DARZALEX the best multiple myeloma drug launch in history and one of the top five most successful launches in cancer. Most importantly, that means more patients with multiple myeloma are getting help.

We reported promising cervical cancer data from the Phase I/II study of tisotumab vedotin. Based on the data we are starting a potentially registrational Phase II study for patients with advanced cervical cancer. This study will be conducted together with Seattle Genetics following their decision to opt in to co-develop and co-commercialize tisotumab vedotin with Genmab last August.

In 2017, we doubled our proprietary clinical product pipeline with the submission of investigational new drug applications (INDs) for the HexaBody<sup>®</sup>-DR5/DR5 and DuoBody<sup>®</sup>-CD3xCD20 programs. These are the first Genmab proprietary antibodies developed with the DuoBody and HexaBody technologies to enter the clinic.

Our growing revenue from DARZALEX royalties allows us to continue to invest in our innovative product pipeline and we are also building our commercialization and launch capabilities. As we work towards our 2025 vision, we will continue to grow and build the company to add the skills and competencies necessary to market our own product in the future.

2017 was a successful year for Genmab and I very much look forward to further describing our progress at the Annual General Meeting. However, if you are unable to attend, I encourage you to return the enclosed proxy, or to vote by post. Thank you for your continued support.

Sincerely yours,

A handwritten signature in blue ink, appearing to read "Jan van de Winkel", with a long horizontal flourish extending to the right.

Jan van de Winkel, Ph.D.  
President & Chief Executive Officer